What You Should Know:
- The FDA just extended its research collaboration
agreement (RCA) with COTA, specifically looking at how COVID-19 is affecting
cancer.
- With this expanded agreement, COTA and the FDA will use real-world data to explore the impact of COVID-19 and the pandemic on cancer treatment, with the opportunity to expand into other oncology questions in the future.
COTA, Inc., a healthcare technology
company that uses real-world data to bring clarity to cancer care,
Read More
Oncology Technology Solutions, Services Impacting Patients and Providers
Redox Integrates Voluntis’ Digital Therapeutics Within EHR
What You Should Know:
- Voluntis forms a strategic partnership with Redox to integrate Voluntis' digital therapeutics within existing clinical workflows and EHRs.
- Integration of Voluntis’ Theraxium platform with the
Redox Engine used by more than 900 healthcare organizations using 55 EHRs
across the country.
- The first area of this application will be in oncology,
with future extensions in other therapeutic areas. As a result, clinical staff
will be better equipped to serve each
Read More
Northwestern to Deploy FDA-Cleared Deploy AI-Guided Cardiac Ultrasounds
What You Should Know:
- Northwestern Memorial Hospital is the first in the
nation to deploy FDA-cleared AI-guided ultrasound by Caption Health, including
measurement of ejection fraction – the most widely used measurement to assess
cardiac function.
- Caption Health's AI-guided cardiac ultrasound enables clinicians – including those without experience – to accurately perform diagnostic-quality exams -- accelerating the availability of information and saving lives.
- Caption AI has been
Read More
Impact of COVID-19: 2020 State of Healthcare Performance Improvement Report
What You Should Know:
- Nearly three-quarters of hospital leaders are either
moderately (52%) or extremely (22%) concerned about the financial viability of
their organizations without an effective treatment or vaccine for COVID-19,
according to a new report from Kaufman Hall entitled, “2020 State of Healthcare
Performance Improvement Report: The Impact of COVID-19”
- One-third of respondents saw operating margin declines
in excess of 100% in the second quarter of 2020 compared with the
Read More
Thriving in a Value-Based Care Environment: Impacting Outcome-to-Cost Ratio
As the COVID-19 pandemic creates surges in acute care, many imaging departments are experiencing a decrease in volume, due to patients deferring or canceling non-urgent appointments and surgeries. The impact of this makes it painfully obvious that -- because imaging departments rely on a fee-for-service model – when the volume is down, finances suffer. As an aspect of healthcare that has historically been hyper-focused on volume, adoption of a value-based care approach in radiology has evolved
Read More
Syapse Appoints David Pomerantz as Chief Commercial Officer
Syapse, a real-world evidence company accelerating the delivery of precision medicine through the Syapse Learning Health Network™, today announced the appointment of David Pomerantz as Chief Commercial Officer. In his new role as Chief Commercial Officer, Pomerantz will lead the future direction of Syapse’s commercial endeavors and expand its life sciences partnerships across the Syapse Learning Network.
Pomerantz Bio/Background
Mr. Pomerantz brings more than 25 years of account
Read More
Biofourmis Lands $100M to Expand AI-Powered Digital Therapeutics Platform
What You Should Know:
- Boston-based digital therapeutics leader Biofourmis
just closed a $100 million Series C funding round led by SoftBank,
bringing its total funding to $145M.
- Biofourmis will be using the funding to develop, validate and commercialize several released and unreleased digital therapeutics solutions across cardiology, oncology, respiratory, and pain, with a focus on the United States and key Asian markets, including Asia Pacific, China, and
Read More
CancerIQ Raises $5M to Expand Genetic Cancer Risk Assessment Platform
What You Should Know:
- CancerIQ raises $5M in Series A funding led by HealthXVentures to accelerate the growth of its genetic cancer risk assessment platform to identify and manage patients at high risk of cancer.
- CancerIQ’s technology enables hospitals to use genomics
to personalize the prevention and early detection of cancer.
- Two new hires recently joined CancerIQ’s newly formed
Integrated Products team from Epic, with the goal of advancing CancerIQ’s
integration with leading
Read More
FDA, Syapse Expand Research to Generate Real-World Data Related to COVID-19 and Cancer
What You Should Know:
The FDA and Syapse announce research collaboration expansion
to address urgent public health challenges including supporting FDA’s goal of
rapid understanding of COVID-19.
As part of the research, Syapse is partnering with FDA’s
Oncology Center of Excellence to investigate methods to derive RWD from
multiple sources including electronic health records, registries and molecular
data
Syapse, a real-world
evidence company accelerating the delivery of precision
Read More
M&A Analysis: 3 Benefits of Siemens Healthineers’ $16.4B Acquisition of Varian Medical
What You Should Know:
- Siemens Healthineers and Varian Medical announce a $16.4B deal in an all-cash transaction on 2nd August 2020.
- Deal expected to close in 1H 2021.
- Varian Medical will maintain its brand name and operate “independently”
- Siemens AG will drop holding in Siemens Healthineers from 85% to 72% as part of the transaction.
News of the deal between Siemens Healthineers and Varian Medical will have caught many industry onlookers off guard on Sunday evening.
Read More
